BioVersys AG (XSWX:BIOV) Other Current Assets: CHF6.46 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BIOV BioVersys AG XSWX:BIOV
4 GF Score
Price CHF26.50
View Full Analysis

What is BioVersys AG Other Current Assets?

BioVersys AG XSWX:BIOV -1.85% 4 Other Current Assets is CHF6.46 Mil as of Dec. 2025. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100.

BioVersys AG's other current assets for the quarter that ended in Dec. 2025 was CHF6.46 Mil.

BioVersys AG's quarterly other current assets declined from Dec. 2024 (CHF1.75 Mil) to Jun. 2025 (CHF0.00 Mil) but then increased from Jun. 2025 (CHF0.00 Mil) to Dec. 2025 (CHF6.46Mil).

BioVersys AG's annual other current assets increased from . 20 (CHF0.00 Mil) to Dec. 2024 (CHF1.75 Mil) increased from Dec. 2024 (CHF1.75 Mil) to Dec. 2025 (CHF6.46 Mil).


BioVersys AG Other Current Assets Related Terms


BioVersys AG Other Current Assets Historical Data

* Premium members only.

The historical data trend for BioVersys AG's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Other Current Assets Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
Other Current Assets
1.75 6.46

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
Other Current Assets 0.00 1.75 0.00 6.46
XSWX:BIOV
4GF Score
BioVersys AG XSWX:BIOV
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of CHF6.46 Mil mean?
BioVersys AG (XSWX:BIOV) has a Other Current Assets of CHF6.46 Mil as of Dec. 2025. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on BioVersys AG.
Is BioVersys AG's Other Current Assets too high?
BioVersys AG's current Other Current Assets is CHF6.46 Mil. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Other Current Assets compare to VRTX and REGN?
BioVersys AG's Other Current Assets of CHF6.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Biotechnology company?
A good Other Current Assets depends on the Biotechnology industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on BioVersys AG. BioVersys AG's current Other Current Assets is CHF6.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current Other Current Assets of CHF6.46 Mil. The current Other Current Assets is CHF6.46 Mil. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current Other Current Assets is CHF6.46 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKW33:Germany
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score

Get the complete analysis for XSWX:BIOV

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF26.50
Price